Treatment Burden During Chronic Kidney Care: A Comprehensive Review for Clinicians

Abstract

Chronic kidney disease (CKD) presents a significant challenge not only due to its progressive nature and associated comorbidities but also because of the substantial treatment burden imposed on patients undergoing chronic kidney care. This review aims to dissect the multi-dimensional aspects of treatment burden in CKD, focusing on epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, and management strategies. Emphasis is placed on recent advances, emerging therapies, and evidence-based guideline recommendations to inform optimal clinical practice. Recognizing and addressing treatment burden is essential for improving adherence, patient outcomes, and quality of life among those affected by CKD.

Introduction

Chronic kidney disease is a prevalent and progressive condition characterized by a gradual loss of renal function over time. Globally, CKD affects approximately 10% of the adult population and is associated with increased morbidity, mortality, and healthcare utilization. The complexity of CKD management, encompassing polypharmacy, dietary restrictions, frequent clinical visits, and the psychological toll of living with a chronic illness, generates a significant treatment burden. For clinicians, understanding and mitigating this burden is critical to optimizing patient-centered care, improving adherence, and ultimately enhancing clinical outcomes.

Epidemiology / Disease Burden

CKD is recognized as a major public health concern with rising prevalence due to aging populations, increasing rates of diabetes, hypertension, and cardiovascular disease. According to recent epidemiological data, CKD ranks among the top causes of years lived with disability globally. Treatment burden in this context refers to the workload of healthcare management and its impact on patient functioning and well-being. Patients with CKD often contend with multifaceted regimens, including multiple medications, routine laboratory monitoring, dietary and fluid restrictions, and, in advanced stages, renal replacement therapy. The interplay between disease burden and treatment burden is bidirectional, with excessive treatment complexity contributing to non-adherence, poorer outcomes, and diminished quality of life.

Pathophysiology

The underlying pathophysiology of CKD involves progressive nephron loss due to glomerulosclerosis, tubulointerstitial fibrosis, and vascular injury. This leads to impaired excretion of metabolic waste, dysregulation of fluid and electrolyte balance, and activation of maladaptive neurohormonal pathways. The resultant uremic milieu precipitates systemic complications—including anemia, mineral and bone disorders, and accelerated cardiovascular disease—each necessitating additional therapy and monitoring. The inherent complexity of managing CKD and its comorbidities is a key driver of treatment burden, as patients must navigate overlapping and sometimes conflicting interventions.

Risk Factors

Several risk factors contribute to both the development of CKD and the escalation of treatment burden during its course. These include advanced age, diabetes mellitus, hypertension, obesity, family history of renal disease, and exposure to nephrotoxic agents. Socioeconomic factors such as limited health literacy, poor access to care, and financial constraints further compound the treatment burden. Notably, patients with lower socioeconomic status are disproportionately affected, facing greater challenges in managing complex regimens and adhering to recommended care plans.

Clinical Features

CKD is often asymptomatic in its early stages, with clinical manifestations emerging as renal function declines. Common features include fatigue, edema, hypertension, anemia, pruritus, and bone pain. As the disease progresses, patients may experience symptoms related to uremia and complications from secondary hyperparathyroidism or cardiovascular disease. The cumulative impact of these symptoms, combined with the demands of ongoing treatment, contributes to the overall burden experienced by patients.

Diagnosis

Diagnosis of CKD is based on the presence of reduced glomerular filtration rate (GFR) <60 mL/min/1.73m² and/or evidence of kidney damage (e.g., albuminuria, structural abnormalities) persisting for more than three months. Assessment involves serial measurement of serum creatinine, estimation of GFR, urinalysis, and evaluation for secondary causes. Risk stratification tools and prognostic scoring systems are increasingly utilized to guide the frequency and intensity of monitoring, aiming to balance early detection of complications with minimization of unnecessary healthcare contacts that may add to treatment burden.

Treatment & Management

Management of CKD is multifaceted, encompassing interventions to slow disease progression, manage complications, and prepare for renal replacement therapy when indicated. Core components include optimal blood pressure and glycemic control, renin-angiotensin-aldosterone system blockade, lipid management, dietary modification, and patient education. Polypharmacy is common, with patients often prescribed antihypertensives, phosphate binders, erythropoiesis-stimulating agents, and vitamin D analogs. The complexity of these regimens, combined with frequent laboratory monitoring and lifestyle adjustments, constitutes a significant treatment burden. Multidisciplinary care models, including pharmacist-led medication reviews and dietician support, are advocated to streamline therapy and enhance patient engagement.

Recent Advances / Emerging Therapies

Recent advances in CKD management aim to reduce both disease progression and treatment burden. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and non-steroidal mineralocorticoid receptor antagonists have demonstrated renal and cardiovascular benefits, offering simplified regimens with favorable risk-benefit profiles. Telemedicine and remote monitoring technology now facilitate more flexible follow-up and self-management, potentially decreasing the logistical and psychological burden of frequent clinic visits. Innovations in digital health, such as mobile applications for medication reminders and dietary tracking, further empower patients and support adherence.

Guideline Recommendations

Current clinical practice guidelines from organizations such as KDIGO and the National Kidney Foundation emphasize individualized, patient-centered care that accounts for treatment burden. Recommendations include regular medication reconciliation, shared decision-making, and the integration of patient preferences into care planning. Guidelines advocate for deprescribing unnecessary medications, simplifying dosing regimens, and leveraging multidisciplinary teams to support comprehensive care. The adoption of patient-reported outcome measures is encouraged to systematically assess and address treatment burden as part of routine clinical practice.

Conclusion

Treatment burden during chronic kidney care encompasses the cumulative demands placed on patients in managing their disease, therapies, and comorbidities. Recognizing the impact of treatment burden is essential for clinicians aiming to optimize adherence, improve patient-reported outcomes, and enhance overall quality of life. Recent advances in pharmacotherapy, digital health, and multidisciplinary care models provide new opportunities to mitigate this burden. Ongoing research and guideline evolution will be critical in guiding best practices for the management of CKD, with the ultimate goal of delivering efficient, patient-centered care that minimizes unnecessary complexity while maximizing therapeutic benefit.